Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer Verlag
      Original Publication: Berlin : Springer International, c1991-
    • Subject Terms:
      Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/*agonists ; Hypoglycemic Agents/*administration & dosage; Aged ; Blood Glucose/metabolism ; Blood Pressure ; Body Mass Index ; Body Weight ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/physiopathology ; Female ; Glycated Hemoglobin/metabolism ; Humans ; Italy/epidemiology ; Lipids/blood ; Male ; Middle Aged ; Prevalence ; Retrospective Studies
    • Abstract:
      Aims: Several GLP-1 receptor agonists (GLP-1RA) have become available for the treatment of type 2 diabetes (T2D), and evidence on their beneficial effects has evolved. We evaluated how the clinical phenotype of patients initiating GLP-1RA changed from 2010 to 2018.
      Methods: This was a retrospective study conducted at six diabetes outpatient clinics in Northeast Italy. We collected data of T2D patients who initiated new GLP-1RA between 2010 and 2018. We recorded baseline characteristics, including demographics, anthropometrics, cardiovascular risk factors, glucose control, lipid profile, liver enzymes, renal function and concomitant medications. We recorded updated HbA1c and body weight at follow-up.
      Results: There were 83,116 T2D patients from a general population of ~ 1,380,000 inhabitants. Among 6167 cases of GLP-1RA initiation, 5408 were analyzed after excluding intra-class switchers. Prescription of GLP-1RA increased exponentially, and the change in the type of GLP-1RA reflected waves of their entering the market. From 2010 to 2018, there were significant increases in baseline age, diabetes duration and prevalence of male sex, of cardiovascular disease and of insulin users. Blood pressure and cholesterol levels decreased concomitantly with increasing use of medications for the control of cardiovascular risk. Baseline average HbA1c (8.3% [67 mmol/mol]) and BMI (34 kg/m 2 ) and their improvement after GLP-1RA initiation did not change over time.
      Conclusions: Despite the early positioning of GLP-1RA in T2D treatment algorithms, GLP-1RA have been prescribed in patients with progressively more advanced disease stage and especially in the presence of cardiovascular disease. Optimization of GLP-1RA use in routine clinical practice is still needed.
    • Contributed Indexing:
      Keywords: Effectiveness; Observational study; Pharmacoepidemiology; Real-world
    • Accession Number:
      0 (Blood Glucose)
      0 (Glucagon-Like Peptide-1 Receptor)
      0 (Glycated Hemoglobin A)
      0 (Hypoglycemic Agents)
      0 (Lipids)
    • Publication Date:
      Date Created: 20191102 Date Completed: 20200713 Latest Revision: 20221207
    • Publication Date:
      20231215
    • Accession Number:
      10.1007/s00592-019-01445-z
    • Accession Number:
      31673896